25 completed, 12 terminated, 6 unknown, 1 active not recruiting. 20 Phase 2, 19 Phase 1, 4 Phase 3, 3 Not applicable.
Follow Carcinoma, Squamous Cell of Head and Neck: new trials by email Literature Review of Carcinoma, Squamous Cell of Head and Neck trials Research Report on Carcinoma, Squamous Cell of Head and Neck
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors PF-08046876, Pembrolizumab, Cisplatin - Advanced/Metastatic Solid Tumors, Bladder Cancer | Phase 1 | Recruiting | Pfizer | 540 | 2025-08-20 | 2026-10-13 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma Treatment - Carcinoma, Squamous Cell, Skin Cancer | Unknown | Maastricht University Medical Center | 965 | 2022-01-01 | 2023-08-16 | |
| Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma VCN-01, Durvalumab - Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Unknown | Institut Català d'Oncologia | 20 | 2019-03-20 | 2022-03-28 |
| Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer Experimental arm, Control arm - Carcinoma, Squamous Cell of Head and Neck, Tobacco Use Disorder | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 24 | 2019-03-09 | 2024-06-25 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer ilixadencel, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma | Phase 1 | Terminated | Mendus | 21 | 2019-01-14 | 2022-03-16 |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Nivolumab Injection, Radiotherapy (RT) - Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma | Phase 2 | Completed | Robert L. Ferris, MD, PhD | 40 | 2018-11-16 | 2025-01-13 |
| ctDNA as a Biomarker for Treatment Response in HNSCC Blood draw - Carcinoma, Squamous Cell of Head and Neck | Not applicable | Completed | The Netherlands Cancer Institute | 70 | 2018-07-16 | 2024-02-01 |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck Nivolumab and Ipilimumab, Docetaxel - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | AIO-Studien-gGmbH | 54 | 2018-07-16 | 2022-11-18 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors tisotumab vedotin, pembrolizumab, carboplatin - Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 350 | 2018-06-25 | 2026-07-22 |
| Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors Durvalumab, Tremelimumab, Cisplatin (dose level 4) - Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | AstraZeneca | 105 | 2018-05-02 | 2025-01-14 |
| Biomarker-based Study in R/M SCCHN Afatinib, Palbociclib, standard of care - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 340 | 2017-11-16 | 2023-11-03 |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC CV8102, CV8102 + anti-PD-1 therapy - Melanoma (Skin), Squamous Cell Carcinoma of the Skin | Phase 1 | Unknown | CureVac | 98 | 2017-09-25 | 2021-11-04 |
| NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck NC-6004, Cetuximab, 5-FU - Carcinoma, Squamous Cell of Head and Neck | Phase 1 / Phase 2 | Completed | NanoCarrier Co., Ltd. | 1 | 2017-03-01 | 2019-04-29 |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors SGN-2FF, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell | Phase 1 | Terminated | Seagen Inc. | 47 | 2017-02-23 | 2019-07-19 |
| Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) avelumab, radiotherapy, cetuximab - Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | The Netherlands Cancer Institute | 10 | 2017-02-01 | 2019-12-11 |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss Copanlisib, Cetuximab - Carcinoma, Squamous Cell of Head and Neck | Phase 1 / Phase 2 | Terminated | UNICANCER | 11 | 2016-06-01 | 2021-03-29 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin - Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Completed | AstraZeneca | 32 | 2016-04-28 | 2020-08-20 |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy Cetuximab, radiation, Docetaxel - Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 60 | 2016-04-01 | 2016-04-27 |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Reirradiation, MK-3475 - Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | Dan Zandberg | 48 | 2016-03-09 | 2025-03-06 |
Showing 20 of 45. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (45) · Head and Neck Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (8) · Carcinoma, Squamous Cell (8) · Recurrence (4) · Carcinoma (3) · Melanoma (3) · Neoplasm Metastasis (3) · Small Cell Lung Carcinoma (3) · Anus Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Pancreatic Neoplasms (2) · Urinary Bladder Neoplasms (2)
Neoplasms by Histologic Type (45) · Neoplasms by Site (45) · Neoplasms, Glandular and Epithelial (45) · Neoplasms (44) · Carcinoma (42) · Carcinoma, Squamous Cell (37) · Head and Neck Neoplasms (33) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Lung Diseases (9) · Lung Neoplasms (9) · Neoplasms, Squamous Cell (9) · Thoracic Neoplasms (9)
Cisplatin (12) · Cetuximab (11) · Carboplatin (6) · pembrolizumab (6) · Fluorouracil (5) · durvalumab (4) · Afatinib (3) · Docetaxel (3) · Radiotherapy, Intensity-Modulated (3) · Nivolumab (2) · Radiotherapy (2) · Surgical Procedures, Operative (2) · ficlatuzumab (2) · palbociclib (2) · tremelimumab (2)
AstraZeneca (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Merck KGaA, Darmstadt, Germany (2) · Pfizer (2) · The Netherlands Cancer Institute (2) · UNICANCER (2) · University of Pittsburgh (2) · Washington University School of Medicine (2) · AIO-Studien-gGmbH (1) · Assistance Publique - Hôpitaux de Paris (1) · Celgene (1) · CureVac (1) · Dan Zandberg (1) · Dana-Farber Cancer Institute (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1)
United States (23) · France (12) · Spain (9) · Germany (8) · Italy (7) · United Kingdom (6) · Belgium (5) · Netherlands (5) · Poland (4) · South Korea (4) · Australia (3) · Japan (3) · Romania (3) · Taiwan (3) · Canada (2)
Robert Ferris, MD, PhD (2) · Abrahim Al-Mamgani, MD, PhD (1) · Ahmad Wehbe, MD (1) · Amar Patel, MD (1) · Atsushi Osada, Study Director (1) · Baris Karakullukcu, MD (1) · Chao-Jung Tsao, Dr. (1) · Christina Derleth, MD (1) · Christophe Le Tourneau (1) · Dan Zandberg, MD (1) · Danielle Eekers, Dr. (1) · David Goldenberg, MD (1) · Douglas Adkins, M.D. (1)
PMID 24807889, PMID 25952795, PMID 27028666, PMID 27044938, PMID 27810904, PMID 27849340, PMID 29346507, PMID 29549159, PMID 29643063, PMID 29931076, PMID 30307465, PMID 31351869, PMID 31563412, PMID 32144134, PMID 32665297, PMID 33004905, PMID 34322775, PMID 34418665, PMID 36319717, PMID 37489066, PMID 37531234, PMID 39904560, PMID 41044356
2017 (3), 2015 (1), 2018 (1), 2023 (1), 2025 (1), R21CA130241 (1)